May 15, 2008

Quigley announces successful infectious bronchitis study

Press Release
 

The Quigley Corporation announced positive results from a study conducted by its wholly owned subsidiary, Quigley Pharma Inc., which was conducted in chickens to evaluate the anti-viral activity of its compound QR448(a).

The compound was administered to chicks that had been infected with Infectious Bronchitis Virus (IBV). The data from the study indicated that QR448(a) is efficacious against an IBV challenge in two week old specific pathogen free (SPF) chicks, confirming previous results indicating that treatment with QR448(a) before or after viral exposure has the potential to lessen or prevent disease.

Preventing and treating infectious bronchitis caused by IBV is a worldwide concern of the poultry industry which calculates its loses due to this disease in lowered weight gains and feed efficiency in broilers, lowered production and quality of eggs in layers and breeders, mortality, clean-up costs and disruption to operations.

The company initiated its investigations into the effectiveness of this compound based on feedback from poultry industry leaders who expressed an increasing need for additional products to combat Infectious Bronchitis (IBV).

With the completion of this latest study and the current dossier of data the company plans to solicit the poultry industry for additional guidance and potential interest and opportunities for developing this compound jointly toward commercialisation.

About The Quigley Corporation

The Quigley Corporation is a diversified natural health medical science company. Its subsidiary Quigley Pharma Inc. conducts research in order to develop and commercialise a pipeline of patented botanical and naturally derived potential prescription drugs.